Last reviewed · How we verify
Primacaine (metabutoxycaine)
Primacaine (generic name: metabutoxycaine) is a metabutoxycaine drug. It is currently in unknown development.
Primacaine works by blocking sodium channels in nerve cells to prevent the transmission of pain signals.
Primacaine, also known as metabutoxycaine, is a local anesthetic used in dentistry. It is a small molecule with the U.S. patent number 2,882,296.
At a glance
| Generic name | metabutoxycaine |
|---|---|
| Drug class | metabutoxycaine |
| Therapeutic area | Pain |
| Phase | unknown |
Mechanism of action
Imagine your nerve cells are like a busy highway where signals are constantly being sent and received. Primacaine is like a roadblock that prevents pain signals from getting through, providing relief from pain. This is achieved by blocking the flow of sodium ions into the nerve cells, which is essential for the transmission of pain signals.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Primacaine CI brief — competitive landscape report
- Primacaine updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Primacaine
What is Primacaine?
How does Primacaine work?
What is the generic name of Primacaine?
What drug class is Primacaine in?
What development phase is Primacaine in?
Related
- Drug class: All metabutoxycaine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing